Mineralys surges as blood pressure drug meets trial goals

Mineralys Therapeutics

10/03/2025 12:23

** Drug developer Mineralys Therapeutics' MLYS.O shares surge 50.42% to $15.82 premarket

** MLYS says its experimental drug, lorundrostat, met the main goals of mid-and late-stage trials

** In the late-stage trial, co's drug reduced blood pressure by 9.1 mmHg (millimeters of mercury) at 6 weeks, compared with placebo

** Lorundrostat inhibits production of aldosterone, a hormone that can contribute to high blood pressure

** In the mid-stage trial, the drug reduced blood pressure by placebo-adjusted 7.9 mmHg

** Stock has fallen 24.7% in the last 12 months

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com;))